SI-BONE has announced it has completed a $33 million growth capital round of financing.

SI-BONE, headquartered in San Jose, Calif., is a sacroiliac joint medical device company that develops tools and products for diagnosing and treating patients with low back issues related to SI joint disorders.

Orbimed and Novo A/S were new investors in the round, joining current investors Skyline Ventures and Montreux Equity Partners.

Proceeds from the investment will be used to fund a number of SI-BONE’s ventures, including expansion of the company’s U.S. sales organization; additional resources in R&D, medical affairs, regulatory, compliance and reimbursement; expansion of operations outside the U.S. through pursuit of regulatory approvals in over a dozen countries in Asia, the Middle East and South America; and initiation of commercialization in Australia, New Zealand and Hong Kong.